Entrada Therapeutics, Inc.
TRDA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001689375
In the last 90 days, Entrada Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 128 institutions reported holding it in 13F filings for Q2 2026, worth $214.4M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Entrada Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 102
- +5 vs. Q3 2024
- Shares held
- 30.6M
- +537.0K (+1.8%) vs. Q3 2024
- Total value
- $529.8M
- +$48.7M (+10.1%) vs. Q3 2024
- New holders
- 19
- 43 more added
- Sold out
- 14
- 24 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TRDA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 128 | $214.4M |
| Q1 2026 | 119 | $321.4M |
| Q4 2025 | 113 | $251.0M |
| Q3 2025 | 116 | $164.8M |
| Q2 2025 | 107 | $198.8M |
| Q1 2025 | 110 | $274.5M |
| Q4 2024 | 102 | $529.8M |
| Q3 2024 | 97 | $481.1M |
| Q2 2024 | 84 | $423.1M |
| Q1 2024 | 77 | $368.8M |
| Q4 2023 | 62 | $396.6M |
| Q3 2023 | 55 | $411.4M |
| Q2 2023 | 56 | $389.9M |
| Q1 2023 | 53 | $361.0M |
| Q4 2022 | 47 | $334.2M |
| Q3 2022 | 33 | $386.4M |
| Q2 2022 | 38 | $301.8M |
| Q1 2022 | 48 | $242.8M |
| Q4 2021 | 46 | $433.8M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Entrada Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Parallel Advisors, LLC | 16 | $277 | 0.00% | +16 | New |
| EverSource Wealth Advisors, LLC | 14 | $242 | 0.00% | +14 | New |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −100,106−100.0% | Sold out |
| Corton Capital Inc. | 0 | $0 | 0.00% | −57,849−100.0% | Sold out |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −57,331−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −41,568−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −39,670−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −36,577−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −15,681−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −15,514−100.0% | Sold out |
| State Board of Administration of Florida Retirement System | 0 | $0 | 0.00% | −14,769−100.0% | Sold out |
| EntryPoint Capital, LLC | 0 | $0 | 0.00% | −12,918−100.0% | Sold out |
| Sherbrooke Park Advisers LLC | 0 | $0 | 0.00% | −11,553−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −1,017−100.0% | Sold out |
| Capital Performance Advisors LLP | 0 | $0 | 0.00% | −71−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −45−100.0% | Sold out |